Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer

British Journal of Cancer

Volumn 108, Issue 4, 2013, Pages 881-886

  Van Der Gun, B T F ^a   Huisman, C ^a   Stolzenburg, S ^a,b   Kazemier, H G ^a   Ruiters, M H J ^a,c   Blancafort, P ^b,d   Rots, M G ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Synvolux Therapeutics Inc   (Netherlands)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

ATFs; EpCAM; ovarian cancer; zinc fingers

Indexed keywords

COMPLEMENTARY DNA; EPITHELIAL CELL ADHESION MOLECULE; SMALL INTERFERING RNA; ZINC FINGER PROTEIN;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CELL GROWTH; CELL SURVIVAL; CYTOTOXICITY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; FEMALE; HUMANS; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; ZINC FINGERS;

EID: 84875213177     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.45     Document Type: Article

References (30)

1. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D, Brenton JD (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221: 49-56.
2. Baeuerle PA, Gires O (2007) EpCAM (CD326) finding its role in cancer. Br J Cancer 96: 417-423.
3. Beerli RR, Dreier B, Barbas III CF (2000) Positive and negative regulation of endogenous genes by designed transcription factors. Proc Natl Acad Sci USA 97: 1495-1500.
4. Beltran AS, Blancafort P (2011) Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs). Epigenetics 7: 350-360.
5. De Groote ML, Verschure PJ, Rots MG (2012) Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes. Nucleic Acids Res 40: 10596-10613.
6. Emmanuel C, Gava N, Kennedy C, Balleine RL, Sharma R, Wain G, Brand A, Hogg R, Etemadmoghadam D, George J. Australian Ovarian Cancer Study Group,Birrer MJ, Clarke CL, Chenevix-Trench G, Bowtell DD, Harnett PR, deFazio A (2011) Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. PLoS One 6: e17617.
7. Gommans WM, McLaughlin PM, Lindhout BI, Segal DJ, Wiegman DJ, Haisma HJ, van der Zaal BJ, Rots MG (2007) Engineering zinc finger protein transcription factors to downregulate the epithelial glycoprotein-2 promoter as a novel anti-cancer treatment. Mol Carcinogen 46: 391-401.
8. Gostner JM, Fong D, Wrulich OA, Lehne F, Zitt M, Hermann M, Krobitsch S, Martowicz A, Gastl G, Spizzo G (2011) Effects of EpCAM overexpression on human breast cancer cell lines. BMC Cancer 11: 45.
9. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, Heinzelmann M, Kalish LH, Bali A, Kench JG, Edwards LS, Vanden Bergh PM, Hacker NF, Sutherland RL, O'Brien PM (2004) Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 10: 4427-4436.
10. Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, Lu KH, Skates SJ, Cramer DW, Berkowitz RS, Mok SC (2003) Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 9: 4782-4791.
11. Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP, LaRochelle JC, Shuch B, Zisman A, Kabbinavar FF, Belldegrun AS (2009) Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res 15: 1162-1169.
12. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M, Gires O (2009) Nuclear signalling by tumourassociated antigen EpCAM. Nat Cell Biol 11: 162-171.
13. Meirelles K, Benedict LA, Dombkowski D, Pepin D, Preffer FI, Teixeira J, Tanwar PS, Young RH, Maclaughlin DT, Donahoe PK, Wei X (2012) Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc Natl Acad Sci USA 109: 2358-2363.
14. Motohara T, Masuko S, Ishimoto T, Yae T, Onishi N, Muraguchi T, Hirao A, Matsuzaki Y, Tashiro H, Katabuchi H, Saya H, Nagano O (2011) Transient depletion of p53 followed by transduction of c-Myc and K-Ras converts ovarian stem-like cells into tumor-initiating cells. Carcinogenesis 32: 1597-1606.
15. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, Cole DJ, Gillanders WE (2004) EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64: 5818-5824.
16. Ralhan R, Cao J, Lim T, MacMillan C, Freeman J, Walfish P (2010) EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis. BMC Cancer 10: 331.
17. Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ (2012) Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer 49: 132-141.
18. Richter CE, Cocco E, Bellone S, Silasi DA, Ruttinger D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD (2010) High-grade, chemotherapyresistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Am J Obstet Gynecol 203: 582.e1-582.e7.
19. Sankpal NV, Mayfield JD, Willman MW, Fleming TP, Gillanders WE (2011) Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion. Breast Cancer Res 13: R124.
20. Sankpal NV, Willman MW, Fleming TP, Mayfield JD, Gillanders WE (2009) Transcriptional repression of epithelial cell adhesion molecule contributes to p53 control of breast cancer invasion. Cancer Res 69: 753-757.
21. Schnell U, Dijk F, Sjollema KA, Giepmans BN (2012) Immunolabeling artifacts and the need for live-cell imaging. Nat Methods 9: 152-158.
22. Sera T (2009) Zinc-finger-based artificial transcription factors and their applications. Adv Drug Deliv Rev 61: 513-526.
23. Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Baeuerle PA, Mueller-Holzner E, Marth C, Gastl G, Zeimet AG (2006) Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 103: 483-488.
24. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, Maurer R, Metzger U, von Castelberg B, Bart R, Stopatschinskaya S, Kochli OR, Haas P, Mross F, Zuber M, Dietrich H, Bischoff S, Mirlacher M, Sauter G, Gastl G (2004) High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 86: 207-213.
25. Stolzenburg S, Rots MG, Beltran AS, Rivenbark AG, Yuan X, Qian H, Strahl BD, Blancafort P (2012) Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res 40: 6725-6740.
26. Uil TG, Haisma HJ, Rots MG (2003) Therapeutic modulation of endogenous gene function by agents with designed DNA-sequence specificities. Nucleic Acids Res 31: 6064-6078.
27. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG (2010) EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31: 1913-1921.
28. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
29. Went P, Dirnhofer S, D S, Moch H, Spizzo G (2008) Expression and prognostic significance of EpCAM. J Cancer Mol 3: 169-174.
30. Went PTH, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S (2004) Frequent EpCAM protein expression in human carcinomas. Hum Pathol 35: 122-128.